GAMMA Investing’s Standard BioTools LAB Stock Holding History

GAMMA Investing’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-270	Closed	-$222	–	4367
2026 Q2	$222	Buy	+270	New	+$255	﹤0.01%	4080
2026 Q1	–	Sell	-735	Closed	-$941	–	4184
2025 Q4	$941	Buy	+735	New	+$987	﹤0.01%	3805

Other funds holding LAB

DIM

DLK Investment Management Solana Beach, California $275M AUM 10.69% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

GAMMA Investing's LAB Position: Q3 2026 in Review

GAMMA Investing sold out of Standard BioTools (LAB) in Q3 2026, closing a stake of 270 shares — an estimated $222 sold.

GAMMA Investing first reported a position in LAB in Q4 2025 and held it in 2 quarters. The position peaked at $941 in Q4 2025. 3 funds tracked by Wall St. Rank hold LAB as of Q3 2026.

GAMMA Investing reported no remaining Standard BioTools position as of Q3 2026 after selling out during the quarter.
GAMMA Investing sold 270 Standard BioTools shares in Q3 2026, an estimated $222.
GAMMA Investing first reported a position in Standard BioTools in Q4 2025 and held it in 2 quarters.
GAMMA Investing's Standard BioTools position peaked at $941 in Q4 2025.
3 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.